Ken Cunningham, formerly chief executive of SkyePharma Plc, has become a member of the board of Verona Pharma Plc as a non-executive director. He is joined on the board by Anders Ullman, former head of research and development at Baxter Biosciences and Nycomed Pharma Pvt Ltd. Verona is developing medicines to treat respiratory diseases.
Dr Cunningham has considerable experience in the respiratory medicine sector, both as a former SkyePharma CEO and former head of Arakis Ltd (now Sosei). Dr Ullman has been head of R&D at Baxter, Nycomed and Biovitrum and executive vice president for global product development at Bayer Healthcare.
Verona Pharma announced the appointments on 8 September 2015.
Copyright 2015 Evernow Publishing Ltd